Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

orbed over time by the vascular tissue as part of the body's normal processes. If clinical results are positive, bioabsorbable drug eluting stents could eventually offer an alternative to the metallic drug eluting stents available to patients today.

About XIENCE V

Abbott's market-leading XIENCE V drug eluting stent was approved by the U.S. Food and Drug Administration and launched in July 2008, and was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at www.xiencev.com.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... The Astellas European Foundation is delighted to announce the winner ... of the University of Geneva, Switzerland Last evening, ... of US$ 300,000 to support work on their project entitled ... liver transplantation for hepatocellular carcinoma , at the Astellas European ...
... 2011 Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: ... will be presenting at two upcoming investor conferences taking place ... Mr. Shortall will present at the Rodman and Renshaw Annual ... On Wednesday, September 14, Mr. Shortall will present ...
Cached Medicine Technology:The Astellas European Foundation Winner of Transplantation Grant 2011 Announced 2Unilife to Participate in Two Investor Conferences 2
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back ... hip pain, neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received ... went on to earn his title of Doctor of Chiropractic from the Palmer College ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. Elyson ... For just $199, patients can currently receive a one hour treatment of this teeth ... but it includes a number of unique features that can turn teeth up to ...
(Date:8/28/2015)... La Mirada, Ca (PRWEB) , ... August 28, ... ... are now administering medical evaluations for those seeking to go deep sea diving. ... pressure, possible oxygen toxicity, and decompression sickness; for these reasons, it is vital ...
(Date:8/28/2015)... Washington, DC (PRWEB) , ... ... ... Atlantic Information Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive ... newest CMS-backed alignment demonstration approved for a December 2015 launch; and Idaho’s ...
(Date:8/28/2015)... ... ... External Counterpulsation, also known as ECP or EECP, is a proven treatment ... ECP) machines with a full clinic licence to help people prevent and reverse heart ... prevent and reverse heart disease through its evidence-based integrative approach to heart ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... research center focused,on improving the quality of life of ... Chattanooga, led by a world-renowned researcher whose,concepts and tools ... The Siskin Center for Child and Family Research ... nonprofit organization focused,on education, outreach and support for children ...
... DIEGO, Dec. 3 Cardium Therapeutics,(Amex: ... presenting a webcast providing,an investor presentation, corporate update ... The webcast will be presented following the ... and can be accessed at, http://www.investorcalendar.com/IC/CEPage.asp?ID=138418 at ...
... place objects in the wound, researchers say , , ... disorder where people wound themselves and then place ... among American teens, especially girls, researchers say. , ... Radiological Society of North America,s annual meeting in ...
... 3 NewCardio, Inc.,(OTC Bulletin Board: NWCI) a cardiac ... a restructure of the going-forward terms of,its December 27, ... investors,in the transaction have exercised a portion of their ... sheet. This will extend the,Company,s cash reserves to ...
... of New York State,s Metro Services has chosen BRANDEMiX, the NYC-based ... brand and launch an employee communications campaign in support of their ... ... December 3, 2008 -- The Cerebral Palsy Associations of New York ...
... their family and friends put their feet where their mouths were on ... charity in the inaugural HBA Great Australian Run. , ... Melbourne, VIC ... employees and their family and friends put their feet where their mouths ...
Cached Medicine News:Health News:Siskin Center for Child and Family Research to Focus on Early Childhood Development and Special Education 2Health News:Siskin Center for Child and Family Research to Focus on Early Childhood Development and Special Education 3Health News:Siskin Center for Child and Family Research to Focus on Early Childhood Development and Special Education 4Health News:Cardium Announces Investor Presentation and Corporate Update Webcast 2Health News:'Self-Embedding' a Troubling Trend Among Teens 2Health News:NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure 2Health News:NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure 3Health News:NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure 4Health News:NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure 5Health News:NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure 6Health News:BRANDEMiX Selected to Launch Cerebral Palsy Associations of NYS Metro Services New Strategic Plan 2Health News:HBA People Walk the Talk for Better Health in the HBA Great Australian Run 2
...
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
Lumbar External Drainage System (LED) with Touhy needle is indicated for temporary access to the Lumbar Subarachnoid region as a means of draining cerebral spinal fluid (CSF) in order to reduce incre...
Medicine Products: